Intuitive Surgical, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, recently announced its financial results for the first quarter of 2024. The company reported significant growth and achievements in various aspects of its operations.

During the first quarter of 2024, Intuitive saw a 16% increase in worldwide da Vinci procedures compared to the same period in 2023. The company also placed 313 da Vinci surgical systems, slightly up from 312 in the first quarter of 2023, expanding its installed base to 8,887 systems by the end of March 2024, marking a 14% increase from the previous year.

Revenue for the first quarter of 2024 reached $1.89 billion, an 11% growth from $1.70 billion in the first quarter of 2023. The GAAP net income attributable to Intuitive for the same period was $545 million, or $1.51 per diluted share, compared to $355 million, or $1.00 per diluted share, in the first quarter of 2023. Additionally, the non-GAAP net income attributable to Intuitive for the first quarter of 2024 was $541 million, or $1.50 per diluted share, compared to $437 million, or $1.23 per diluted share, in the same period last year.

Intuitive achieved significant milestones in product development and regulatory approvals during the first quarter of 2024. In January, the company received CE mark certification for the da Vinci single-port (SP) surgical system, enabling its use in various surgical procedures. The company plans to introduce the SP system in select European countries throughout 2024. Moreover, in March 2024, Intuitive obtained FDA clearance for the da Vinci 5, its next-generation multi-port robotic system, expanding its application across surgical specialties.

Overall, Intuitive Surgical’s performance in the first quarter of 2024 reflects its continued growth, innovation, and commitment to advancing minimally invasive surgical technologies.